Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:44 AM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 3,258 matching trials from the local directory fallback.

Filters: Not yet recruiting Clear all

Conditions: Anhedonia, Depression
Interventions: Effort-based Decision-Making Task; Other
Lead sponsor: Georgia Institute of Technology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypothyroidism
Interventions: Levothyroxine Pill, Placebo; Drug
Lead sponsor: Spyridoula Maraka; Other
Eligibility: 65 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 3
States / cities: Little Rock, Arkansas • Gainesville, Florida • Rochester, Minnesota

Conditions: Behavior Change, Digital Intervention, Obesity & Overweight, Perimenopausal Women, Resistance Exercise, Women's Health, glp1 Agonist
Interventions: PLAN-RT 1.0; Behavioral
Lead sponsor: Louisiana State University and A&M College; Other
Eligibility: 40 Years to 59 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Cessation, Nicotine, Cessation, Tobacco, E Cigarette Use
Interventions: Brief Behavioral Counseling, Nicotine Replacement Therapies; Behavioral · Drug
Lead sponsor: West Virginia University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Greenville, North Carolina • Morgantown, West Virginia

Conditions: Triple-Negative Breast Cancer (TNBC)
Interventions: Carboplatin, Paclitaxel (Chemotherapy), Pembrolizumab; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: IDH Wildtype Glioblastoma, MGMT-unmethylated Glioblastoma (GBM)
Interventions: MGMT-unmethylated GBM with Radiation, avutometinib and defactinib for 3 weeks on/1 week off; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Basal Cell Carcinoma, Melanoma, Skin Cancer Excision Site, Squamous Cell Carcinoma
Interventions: Abobotulinumtoxin-A, Control- Saline injection; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Abdominal Cancer Surgery, Cancer, Functional Outcomes, Recovery Outcomes, Surgery
Interventions: Algorithmic Guideline for Functional Recovery following Cancer Surgery; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Frontal Fibrosing Alopecia
Interventions: Delgocitinib; Drug
Lead sponsor: Maryanne Makredes Senna; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Pancreas Cancer
Interventions: Multimedia Video - Based Informed Consent, Standard Informed Consent; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions: Medical Device Usage and Evaluation, Tirzepatide; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Chicago, Illinois • Houston, Texas

Conditions: Lynch Syndrome
Interventions: Let's Talk Genetics Providers, Let's Talk Patients; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lung Cancer (Diagnosis)
Interventions: Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lung Carcinoma
Interventions: Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration, SVN53-67/M57-KLH Peptide Vaccine, Sargramostim; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 1 more

Conditions: Diabetes Mellitus Type 2
Interventions: Harnessing Online Peer Education; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Irvine, California

Conditions: Germ Cell Tumor, Pediatric Solid Tumors, Rhabdomyosarcoma, Sarcoma
Interventions: ICG (Indocyanine Green); Diagnostic Test
Lead sponsor: University of Rochester; Other
Eligibility: 1 Month to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cannabis Use, PTSD, Post Traumatic Stress Disorder, Suicide
Interventions: Cannabidiol (CBD) only, Delta-9-tetrahydrocannabinol (THC) only, Placebo only, THC:CBD 1:1; Drug
Lead sponsor: Leslie Lundahl; Other
Eligibility: 18 Years to 60 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthcare Workers, Lifestyle Risk Reduction, Long Term Care Facility, Occupational Burnout, Older Adults Institutionalized in Residential Homes, Physical Activity, Worksite Health Promotion
Interventions: FFC, WHHIP; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Propofol Injection Pain
Interventions: Lidocaine, Normal saline, Passive arm elevation, Propofol, Sham arm elevation; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Chronic Pain, Mild Cognitive Impairment
Interventions: Feeling of Being, Health Enhancement Program; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Ovarian Insufficiency, Turner Syndrome
Interventions: Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 12 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes
Interventions: Gut motility quantification using a capsule after initiating GLP-1RA therapy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pain
Interventions: Transitional Pain Service; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Disease Risk Factors, Multiple Myeloma
Interventions: Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway; Other
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028
U.S. locations: 1
States / cities: Burlington, Vermont

Search by objective public record fields.

Multimodal Differences in Effort-based Decision-Making in Depression

Discontinuation of Low-Dose Levothyroxine in Older Adults With Subclinical Hypothyroidism

Digital Resistance Training for Midlife Women Using GLP-1

Evaluation of Dependence and Nicotine Replacement Therapy-Supported Cessation Efforts Among Regular Electronic Cigarette Use

Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC

Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

Impact of Dysport on PMFF Donor Scar

Developing Pilot Postoperative Guidelines for Improved Functional Outcomes After High-Risk Cancer Surgery

Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)

SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Overcoming Barriers to Uptake of Cascade Screening

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

Testing the SurVaxM Vaccine for Lung Cancer Prevention

HOPE Intervention for Fitness

Tumor-Lymph Node Mapping

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

Intervention to Increase Physical Activity and Wellbeing Among Staff and Residents in Assisted Living Facilities

Arm Elevation for Prevention of Propofol Injection Pain

Mindfulness-Based Cognitive Therapy Vs. the Health Enhancement Program for Chronic Pain and Early Cognitive Decline; The Feeling of Being Pilot RCT

Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome

Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation

Prospective Randomized Study of TPS + CBT VS TPS Alone: Readmission, Opioid Use, and Chronic Pain

MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma